- Home
- MGNX vs NCSM Comparison
MGNX vs NCSM Comparison
Compare MGNX & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- NCSM
- Stock Information
- Founded
- MGNX 2000
- NCSM 2006
- Country
- MGNX United States
- NCSM United States
- Employees
- MGNX N/A
- NCSM N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- NCSM Oilfield Services/Equipment
- Sector
- MGNX Health Care
- NCSM Energy
- Exchange
- MGNX Nasdaq
- NCSM Nasdaq
- Market Cap
- MGNX 70.3M
- NCSM 61.1M
- IPO Year
- MGNX 2013
- NCSM 2017
- Fundamental
- Price
- MGNX $1.43
- NCSM $31.44
- Analyst Decision
- MGNX Hold
- NCSM
- Analyst Count
- MGNX 10
- NCSM 0
- Target Price
- MGNX $6.83
- NCSM N/A
- AVG Volume (30 Days)
- MGNX 599.1K
- NCSM 9.4K
- Earning Date
- MGNX 05-20-2025
- NCSM 04-30-2025
- Dividend Yield
- MGNX N/A
- NCSM N/A
- EPS Growth
- MGNX N/A
- NCSM N/A
- EPS
- MGNX N/A
- NCSM 3.27
- Revenue
- MGNX $149,962,000.00
- NCSM $168,704,000.00
- Revenue This Year
- MGNX N/A
- NCSM $7.03
- Revenue Next Year
- MGNX $80.86
- NCSM $5.82
- P/E Ratio
- MGNX N/A
- NCSM $9.66
- Revenue Growth
- MGNX 155.26
- NCSM 18.16
- 52 Week Low
- MGNX $0.99
- NCSM $15.90
- 52 Week High
- MGNX $14.91
- NCSM $38.95
- Technical
- Relative Strength Index (RSI)
- MGNX 43.37
- NCSM 52.40
- Support Level
- MGNX $1.54
- NCSM $29.15
- Resistance Level
- MGNX $1.82
- NCSM $32.71
- Average True Range (ATR)
- MGNX 0.15
- NCSM 1.84
- MACD
- MGNX 0.01
- NCSM 0.26
- Stochastic Oscillator
- MGNX 19.79
- NCSM 38.99
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc provides products and support services that facilitate the optimization of oil and natural gas well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's primary offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. Geographically, majority of revenue is generated from United States.